You are here

Paratek

Activist investor NexPoint threatens to block Paratek's $462M sale

Fierce Pharma

Wed, 06/28/23 - 10:31 pm

activist investors

Antibiotic maker Paratek, low on cash, agrees to a buyout

BioPharma Dive

Tue, 06/6/23 - 04:17 pm

Novo Nordisk Foundation

As U.S. calls for stateside manufacturing, antibiotic maker Paratek gambles on 'onshoring' effort

Fierce Pharma

Mon, 06/8/20 - 10:32 am

drug manufacturing

Paratek wins US contract to develop anthrax treatment

BioPharma Dive

Fri, 12/20/19 - 10:15 am

government contracts

Paratek's top antibiotic fails to clear a key competitive hurdle in head-to-head studies

Endpoints

Fri, 11/1/19 - 10:28 am

Paratek caps 20-year R&D journey with FDA OK for its broad spectrum antibiotic — time to talk launch

Endpoints

Wed, 10/3/18 - 09:49 am

Paratek clears one last big hurdle on the way to an FDA marketing decision for antibiotic

Endpoints

Wed, 08/8/18 - 08:11 pm

advisory panels

Paratek antibiotic not inferior to current treatments: FDA staff

Reuters

Tue, 08/7/18 - 12:05 am

aminomethylcyclines

The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs

Yahoo/Benzinga

Sun, 08/5/18 - 07:25 pm

Pain Therapeutics

Vertex Pharmaceuticals

lumacaftor/ivacaftor

After 20 years, Paratek’s broad-spectrum antibiotic is headed to the FDA

Drug Delivery Business News

Thu, 02/15/18 - 10:57 am

broad spectrum antibiotics

New antibiotic therapies: what future?

GoinPharma

Mon, 10/23/17 - 10:00 pm

Tetraphase Pharmaceuticals

Motif Biosciences

The Medicines Company

Paratek goes 3-for-3 in PhIII, but antibiotic stumbles on side effect profile

Endpoints

Tue, 07/18/17 - 09:21 am

clinical trials

Biotech Movers: Sarepta, Paratek, PDL BioPharma

TheStreet.com

Mon, 04/24/17 - 10:14 am

Sarepta Therapeutics

Paratek Pharma shares surge 30% after antibiotic study results

Marketwatch

Tue, 04/4/17 - 12:22 am

Allergan, Paratek Pharma report positive results in late-stage trial of acne treatment

Marketwatch

Mon, 03/27/17 - 10:57 am

Paratek Makes Milestone Movement in Late-Stage Trial

24/7 Wall St

Fri, 06/17/16 - 12:12 pm

clinical trials

skin infections

9 Biotech Picks for 2016

Barron's

Sat, 01/2/16 - 10:19 am

Intra-Cellular Therapies

Seres Therapeutics

Neurocrine Biosciences

How Paratek hopes to succeed in antibiotics despite Tetraphase’s fail

Bizjournals.com

Wed, 10/14/15 - 09:17 am

Pharma Stocks To Keep An Eye On: Pozen Inc. (POZN), Paratek Pharmaceuticals (PRTK), Oncothyreon Inc. (ONTY), Tetraphase Pharmaceuticals (TTPH)

Bidness Etc.

Thu, 12/18/14 - 10:07 am

Tetraphase Pharmaceuticals

Pages